![Paolo Tarantino: Final OS from BROCADE3 phase 3 trial](https://oncodaily.com/pub/uploads/2023/11/download-22-e1701200451814.jpg)
Photo of Paolo Tarantino from X
Feb 10, 2024, 08:06
Paolo Tarantino: Final OS from BROCADE3 phase 3 trial
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“Final OS from BROCADE3 phase 3 trial: adding veliparib to 1L carbo-taxol did not improve OS in BRCA-mutant patients with advanced TNBC. Notably, mPFS (>12 months) and mOS (≃30 months) were longer than expected. Effect of the carbo-taxol combo, or chance?”
Visit the article website.
Source: Paolo Tarantino/X